Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Chief Medical Officer | September 01, 2022 | September 06, 2022 |
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Chief Medical Officer | November 07, 2018 | November 09, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date September 01, 2022 · Filed September 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.04 · Expires 2032-08-31 | Direct | 60,000 |
Reported balance
After 2022-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-01 · Grant · Acquired 60,000 · Balance 60,000 F1: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
CORCEPT THERAPEUTICS INC
Report date November 07, 2018 · Filed November 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-11-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-11-07 · Exercise / conversion · Acquired 8,000 · Balance 8,000 F1: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Row 2 · 2018-11-07 · Sale · Disposed 8,000 · Balance 0 F1: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $13.36 to $13.93 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2025-09-29 | Direct | 329,000 |
Reported balance
After 2018-11-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-11-07 · Exercise / conversion · Disposed 8,000 · Balance 329,000 F1: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares.
F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $13.36 to $13.93 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F3: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2022 Filed Sep 6, 2022 20:42 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001567619-22-017102 · doc1.xml · derivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 17:39 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0001567619-22-002464 · doc1.xml · derivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 22:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-028605 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 22:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $13.74 | $109,887.20 |
DisclosureSEC source: 0000899243-18-028605 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $13.36 to $13.93 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 22:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-028605 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 21:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-026440 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 21:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $13.19 | $105,537.60 |
DisclosureSEC source: 0000899243-18-026440 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $12.98 to $13.33 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 21:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-026440 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 20:36 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-024192 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 20:36 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $14.57 | $116,532.80 |
DisclosureSEC source: 0000899243-18-024192 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $14.22 to $14.81 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 20:36 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-024192 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 21:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-021699 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 21:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $14.15 | $113,184.80 |
DisclosureSEC source: 0000899243-18-021699 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $14.05 to $14.29 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 21:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-021699 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 23:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-019677 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 23:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $15.09 | $120,685.60 |
DisclosureSEC source: 0000899243-18-019677 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $14.74 to $15.31 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 23:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-019677 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-016051 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $18.23 | $145,825.60 |
DisclosureSEC source: 0000899243-18-016051 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $17.90 to $18.93 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-016051 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| May 07, 2018 Filed May 8, 2018 22:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-011920 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| May 07, 2018 Filed May 8, 2018 22:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $17.68 | $141,428.00 |
DisclosureSEC source: 0000899243-18-011920 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $17.55 to $17.775 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| May 07, 2018 Filed May 8, 2018 22:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-011920 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| April 06, 2018 Filed Apr 9, 2018 21:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-009783 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| April 06, 2018 Filed Apr 9, 2018 21:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $16.22 | $129,784.00 |
DisclosureSEC source: 0000899243-18-009783 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $15.91 to $16.63 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| April 06, 2018 Filed Apr 9, 2018 21:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-009783 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-006846 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $15.67 | $125,323.20 |
DisclosureSEC source: 0000899243-18-006846 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $15.34 to $15.88 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-006846 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0000899243-18-003469 · doc4.xml · derivative · entry 4 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-02-07 F4 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2018, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2022. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-003469 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $16.60 | $132,774.40 |
DisclosureSEC source: 0000899243-18-003469 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $16.34 to $16.93 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-003469 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 22:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-000874 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 22:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $18.67 | $149,348.80 |
DisclosureSEC source: 0000899243-18-000874 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $18.34 to $18.91 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 22:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-000874 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 22:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-17-028552 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 22:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,000 | $16.72 | $133,776.00 |
DisclosureSEC source: 0000899243-17-028552 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $16.48 to $16.90 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 22:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-17-028552 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 23:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000899243-17-004040 · doc4.xml · derivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-02-10 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 10, 2017, so that the total number of shares subject to this option becomes fully vested and exercisable on February 10, 2021. Read SEC document |
| February 26, 2016 Filed Feb 14, 2017 23:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000899243-17-004039 · doc5.xml · derivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-02-26 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 26, 2016, so that the total number of shares subject to this option becomes fully vested and exercisable on February 26, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.